

8-16-2004

Similar promotion of Abeta1-42 fibrillogenesis by native apolipoprotein E epsilon3 and epsilon4 isoforms.

David Sweeney

Cornell University Medical College, 1300 York Ave, Room A569, New York, NY 10021 USA

Ralph Martins

Sir James McCusker Alzheimer's Unit, The University of Western Australia, Perth WA, Australia 6009

Harry LeVine

Sanders-Brown Institute on Aging, University of Kentucky, Lexington, KY 40508 USA

Jonathan D Smith

Cleveland Clinic, Cleveland, OH 44195 USA

Sam Gandy

Farber Institute for Neurosciences Thomas Jefferson University 900 Walnut Street, JHN 467 Philadelphia, PA 19107-5587 USA

Follow this and additional works at: <https://jdc.jefferson.edu/farberneursofp>

 Part of the [Neurology Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Sweeney, David; Martins, Ralph; LeVine, Harry; Smith, Jonathan D; and Gandy, Sam, "Similar promotion of Abeta1-42 fibrillogenesis by native apolipoprotein E epsilon3 and epsilon4 isoforms." (2004). *Farber Institute for Neuroscience Faculty Papers*. Paper 1.

<https://jdc.jefferson.edu/farberneursofp/1>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Farber Institute for Neuroscience Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Research

Open Access

Similar promotion of A β ₁₋₄₂ fibrillogenesis by native apolipoprotein E ϵ 3 and ϵ 4 isoforms

David Sweeney¹, Ralph Martins², Harry LeVine III³, Jonathan D Smith⁴ and Sam Gandy*⁵

Address: ¹Cornell University Medical College, 1300 York Ave, Room A569, New York, NY 10021 USA, ²Sir James McCusker Alzheimer's Unit, The University of Western Australia, Perth WA, Australia 6009, ³Sanders-Brown Institute on Aging, University of Kentucky, Lexington, KY 40508 USA, ⁴Cleveland Clinic, Cleveland, OH 44195 USA and ⁵Farber Institute for Neurosciences Thomas Jefferson University 900 Walnut Street, JHN 467 Philadelphia, PA 19107-5587 USA

Email: David Sweeney - sweeney@acom.yu.edu; Ralph Martins - rmartins@cyllene.uwa.edu.au; Harry LeVine - hlevine@email.uky.edu; Jonathan D Smith - smithj@lerner.ccf.org; Sam Gandy* - samgandy3d@aol.com

* Corresponding author

Published: 16 August 2004

Received: 07 August 2004

Journal of Neuroinflammation 2004, 1:15 doi:10.1186/1742-2094-1-15

Accepted: 16 August 2004

This article is available from: <http://www.jneuroinflammation.com/content/1/1/15>

© 2004 Sweeney et al; licensee BioMed Central Ltd.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The apolipoprotein E ϵ 4 allele contributes to the genetic susceptibility underlying a large proportion (~40–60%) of typical, sporadic Alzheimer disease. Apolipoprotein E deficient mice made transgenic for human apolipoprotein E ϵ 4 accumulate excess cerebral amyloid when compared to similarly prepared mice expressing human apolipoprotein E ϵ 3. Therefore, it is important to search for relevant interactions(s) between apolipoprotein E ϵ 4 and A β in order to clarify the biological role for apolipoprotein E ϵ 4 in Alzheimer disease. Using a thioflavine T (ThT)-based assay, we have investigated the effects of native human apolipoprotein E isoforms on the kinetics of A β fibrillogenesis. No obvious profibrillogenic activity was detected in A β ₁₋₄₀-based assays of any native apolipoprotein E isoform. However, when ThT assays were repeated using A β ₁₋₄₂, modest, but statistically significant, profibrillogenic activity was detected in both apolipoprotein E ϵ 3- and apolipoprotein E ϵ 4-containing media and was similar in magnitude for the two isoforms. These data demonstrate that native apolipoprotein E possesses "pathological chaperone"-type activity for A β : in other words, the data indicate that a chaperone-like misfolding reaction can occur between native apolipoprotein E and A β . However, the equipotent activities of the apolipoprotein E ϵ 3 and ϵ 4 isoforms suggests the possibility that either extended co-incubation of apolipoprotein E and A β , or, perhaps, the inclusion in the reaction of other fibrillogenesis-modulation co-factors (such as metal ions, or inflammatory mediators such as reactive oxygen species, α ₂-macroglobulin, apolipoprotein J, etc.) may be required for modeling *in vitro* the apolipoprotein E-isoform-specific-regulation of extracellular A β accumulation that occurs *in vivo*. Alternatively, other events, such as differential apolipoprotein E-isoform-mediated clearance of A β or of apolipoprotein E/A β complexes may underlie apolipoprotein E-isoform-dependent A β accumulation.

Background

Genetic-neuropathological correlation indicates that the apolipoprotein E type ϵ 4 isoform specifies increased cere-

bral [1,2] and cerebrovascular [3] accumulation of amyloid β -protein (A β). In addition, the apolipoprotein E ϵ 2 isoform can apparently prevent the expression of clinical

Alzheimer-type dementia which is otherwise typically associated with amyloidogenic mutations in the amyloid- β protein precursor [4]. Since the apolipoprotein E $\epsilon 4$ allele contributes to the genetic susceptibility underlying a large proportion (~ 40 – 60%) of typical, sporadic Alzheimer disease, it is important to search for relevant interaction(s) between apolipoprotein E $\epsilon 4$ and A β in order to clarify the biological role for apolipoprotein E $\epsilon 4$ in Alzheimer disease. Currently proposed mechanisms include differential activities of apolipoprotein E isoforms in modulating A β fibrillogenesis [5-7] and/or A β clearance [8,9]. Many studies of apolipoprotein E modulation of A β fibrillogenesis have utilized denatured apolipoprotein E, purified from the serum of human apolipoprotein E homozygotes following extraction in organic solvents [10]. While providing a convenient source of pure apolipoprotein E protein, this preparation does not represent native apolipoprotein E as it exists *in vivo*. Using a thioflavine T (ThT)-based assay [11] we have investigated the effects of native human apolipoprotein E isoforms on the kinetics of A β fibrillogenesis.

Methods

Synthetic A β_{1-40} or A β_{1-42} (Keck Foundation Protein Facility, Yale University, New Haven CT) was freshly prepared for each assay at a concentration of 16 mg/ml in distilled, deionized water and diluted with phosphate-buffered saline (PBS) to generate a 5 mg/ml working solution. The "aggregation step" consisted of a reaction mixture containing 8 μ l A β peptide (1 mg/ml final conc) and 32 μ l of either apolipoprotein E $\epsilon 3$ - or $\epsilon 4$ -containing conditioned medium or control conditioned medium from SV40 empty vector-transfected cells.

For the investigation of native apolipoprotein E preparations, apolipoprotein E isoforms were generated in the conditioned medium of stably-transfected SV40-apolipoprotein E $\epsilon 3$ -, or SV40-apolipoprotein E $\epsilon 4$ -, expressing Chinese hamster ovary (CHO) cells (CHO cells lack detectable endogenous apolipoprotein E; data not shown). All conditioned media were prepared using Dulbecco's minimal essential medium supplemented with 0.2% (wt/vol) bovine serum albumin only (no fetal bovine serum). Apolipoprotein E isoform levels were determined by quantitative immunoblotting of conditioned medium and apolipoprotein E-containing serum standards, the latter having been kindly provided by Dr. Petar Alaupovic of the Oklahoma Medical Research Foundation (Oklahoma City OK). Conditioned medium apolipoprotein E concentrations were then standardized using control medium conditioned by SV40 empty vector-transfected cells as diluent, yielding a final concentration of apolipoprotein E of 14 μ g/ml, within the range of that reported in human cerebrospinal fluid. Since the final concentration of A β peptide was 1 mg/ml, the A β /apoli-

poprotein E stoichiometry (molar ratio) was $\sim 500:1$, suggesting models for the A β /apolipoprotein E interaction based either on a "catalytic" "pathological chaperoning" model of apolipoprotein E action on A β , or with a "seeding" model of A β folding. Detailed biochemical characterization of this native apolipoprotein E preparation has been reported [9].

The "aggregation step" fibrillogenesis reaction [11] was incubated at 37°C until the time of the ThT fluorescence measurement, which was performed from 1 to 7 days later. For the "measurement step" [11], 960 μ l of 10 μ M ThT (Nakarai Chemicals, Kyoto, Japan) in 50 mM phosphate buffer (pH 6.0) was added to the "aggregation step" reaction mixture. Within 30 minutes after addition of ThT, fluorescence was measured with a Millipore Cytofluor (Bedford MA) in each of five successive 200 μ l aliquots of the reaction mixture, using an excitation filter of 450 nm and an emission filter of 482 nm, and a temperature of 25°C.

In order to standardize the ThT assay in our Laboratory, we performed studies of A β fibrillogenesis following 1–7 day incubations of A β_{1-40} , either in physiological phosphate buffer alone or in the presence of metal ions (Zn $^{2+}$, Fe $^{2+}$, or Al $^{3+}$; 1 mM final conc [12]. ThT fluorescence and ultrastructural features were measured daily (not shown). Profibrillogenic activities of the metal ions tested were in agreement with a published report [12] (e.g., Al $^{3+}$ -stimulated ThT fluorescence of A β_{1-40} by 3.6 ± 1.1 - to 5.7 ± 1.4 -fold; $p < 0.01$), indicating that our A β preparations were capable of metal ion-induced fibrillogenesis. Metals were not present during assessment of profibrillogenic effects of apolipoprotein E isoforms.

Results and discussion

No obvious profibrillogenic activity was detected in A β_{1-40} -based assays of any native apolipoprotein E isoform (Table 1). However, when ThT assays were repeated using A β_{1-42} , modest, but statistically significant, profibrillogenic activity was detected in both apolipoprotein E $\epsilon 3$ - and apolipoprotein E $\epsilon 4$ -containing media and was similar in magnitude for the two isoforms (Table 1). The observation of a profibrillogenic effect of apolipoprotein E specifically for A β_{1-42} has been noted [5] and is of particular interest in light of biophysical and molecular neuropathological evidence suggesting that "long" A β peptides ending at positions N-42 or N-43 are apparently crucial for the initiation ("seeding") of A β deposition [13].

These data demonstrate that native apolipoprotein E possesses "pathological chaperone"-type activity for A β : in other words, the data indicate that a chaperone-like misfolding reaction can occur between native apolipoprotein

Table 1: Effects of native apolipoprotein E isoforms on fibrillogenesis of A β ₁₋₄₀ and A β ₁₋₄₂. Fold-effects represent means \pm SEM of the quotients of ThT fluorescence values obtained for each A β peptide in the presence of apolipoprotein E-isoform-containing conditioned medium divided by ThT values obtained in the presence of conditioned medium lacking apolipoprotein E, derived from empty vector-transfected cells (n = 5–6).

		A β ₁₋₄₀	
<u>1 day co-incubation</u>	CHO apolipoprotein E ϵ 3	1.0 \pm 0.1-fold	N.S.
	CHO apolipoprotein E ϵ 4	1.0 \pm 0.1-fold	N.S.
<u>7 day co-incubation</u>	CHO apolipoprotein E ϵ 3	1.0 \pm 0.1-fold	N.S.
	CHO apolipoprotein E ϵ 4	1.2 \pm 0.1-fold	N.S.
		A β ₁₋₄₂	
<u>4 day co-incubation</u>	CHO apolipoprotein E ϵ 3	1.7 \pm 0.27-fold	p < 0.01
	CHO apolipoprotein E ϵ 4	1.6 \pm 0.18-fold	p < 0.005
<u>7 day co-incubation</u>	CHO apolipoprotein E ϵ 3	1.7 \pm 0.22-fold	p < 0.005
	CHO apolipoprotein E ϵ 4	1.8 \pm 0.19-fold	p < 0.0005

E and A β , at least at the concentrations and proportions evaluated herein. However, the equipotent activities of the apolipoprotein E ϵ 3 and ϵ 4 isoforms suggests the possibility that either extended co-incubation of apolipoprotein E and A β , or, perhaps, the inclusion in the reaction of other fibrillogenesis-modulation co-factors (such as metal ions, or inflammatory mediators such as reactive oxygen species, α_1 -antichymotrypsin, heparin sulfate-proteoglycan, non-A β component, apolipoprotein J, complement, etc.) may be required for modeling *in vitro* the apolipoprotein E-isoform-specific-regulation of extracellular A β accumulation that occurs *in vivo*.

Alternatively, other events, such as differential apolipoprotein E-isoform-mediated clearance of A β or of apolipoprotein E/A β complexes [8,9,14] may contribute to apolipoprotein E-isoform-dependent A β accumulation. Differential anti-inflammatory activity might also play a role. Further investigation will be required in order to elucidate the precise mechanism(s) which specify how apolipoprotein E ϵ 4 promotes A β accumulation in human brain and cerebral vessels *in vivo*.

List of abbreviations

ThT, thioflavine T; A β , amyloid- β peptide; PBS, phosphate-buffered saline; CHO, Chinese hamster ovary cells.

Competing interests

None declared.

Authors' contributions

DS performed all assays, including the ThT assay, which was originated by HL. HL also oversaw the transfer of the assay from his lab to ours. RM prepared standard conditioned media from transfected cells provided by JDS. SG oversaw the project, supported the project as noted below, and wrote the manuscript.

Acknowledgements

This research was supported by USPHS PPG grant AG10491 to S.G. We thank Jan Naslund and Christer Nordstedt (Karolinska Institute, Stockholm, Sweden) for critical comments and helpful discussion.

References

- Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pelicak-Vance MA, Goldgaber D, Roses AD: **Increased amyloid β -peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.** *Proc Natl Acad Sci USA* 1993, **90**:9649-9653.
- Holtzman D, Bales K, Tenkova T, Fagan A, Parsadanian M, Sartorius L, Mackey B, Olney J, McKeel D, Wozniak D, Paul S: **Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.** *Proc Natl Acad Sci USA* 2000, **97**:2892-2897.
- Greenberg SM, Rebeck GW, Vonsattel JPG, Gomez-Isla H, Hyman BT: **Apolipoprotein E ϵ 4 and cerebral hemorrhage associated with amyloid angiopathy.** *Ann Neurol* 1995, **38**:254-259.
- St George-Hyslop P, Crapper McLachlan D, Tuda T, Rogaev E, Karlinsky H, Lippa CF, Pollen D: **Alzheimer's disease and possible gene interaction.** *Science* 1994, **263**:537.
- Ma J, Yee A, Brewer HB, Das S, Potter H: **Amyloid-associated proteins α_1 -antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β -protein into filaments.** *Nature* 1994, **372**:92-94.
- Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B: **Acceleration of Alzheimer's fibril formation by apolipoprotein E *in vitro*.** *Am J Pathol* 1994, **145**:1030-1035.
- Evans KC, Berger EP, Cho C-G, Weisgraber KH, Lansbury PT: **Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease.** *Proc Natl Acad Sci USA* 1995, **92**:763-767.
- LaDu M, Falduto M, Manelli A, Reardon C, Getz C, Frail D: **Isoform-specific binding of apolipoprotein E to β amyloid.** *J Biol Chem* 1994, **269**:23403-23406.
- Zhou Z, Smith JD, Greengard P, Gandy S: **Alzheimer amyloid- β peptide forms denaturant-resistant complex with type ϵ 3 but not type ϵ 4 isoform of native apolipoprotein E.** *Molecular Medicine* 1996, **2**:175-180.
- Rail SC, Weisgraber KH, Mahley RW: **Isolation and characterization of apolipoprotein E.** *Meth Enzymol* 1986, **128**:273-287.
- LeVine H: **Thioflavine T interaction with synthetic Alzheimer's disease β -amyloid peptides: Detection of amyloid aggregation in solution.** *Protein Science* 1993, **2**:404-410.
- Mantyh P, Ghilardi J, Rogers S, DeMaster E, Allen C, Stimson E, Maggio J: **Aluminum, iron and zinc ions promote aggregation of physiological concentration of β -amyloid peptide.** *J Neurochem* 1993, **61**:1171-1174.

13. Iwatsubo T, Odaka , Suzuki N, Mizusawa H, Nukina N, Ihara Y: **Visualization of A β 42(43) and A β 40 in senile plaques with end-specific A β monoclonals: Evidence that an initially deposited species is A β 42(43).** *Neuron* 1994, **13**:45-53.
14. Naslund J, Thyberg J, Tjemberg L, Wemstedt C, Karlstrom AR, Bogdanovic N, Gandy S, Lannfelt L, Terenius L, Nordstedt C: **Characterization of stable complexes involving apolipoprotein E and the amyloid β -peptide in Alzheimer disease brain.** *Neuron* 1995, **15**:219-228.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

